Michalka J, et al. - Researchers conducted retrospective analysis from a single-center database over the past 17 years, when consolidation high-dose chemotherapy with autologous stem cell transplantation (ASCT) was not a standard therapeutic approach, in order to present the frontline therapy results in unselected patients with primary CNS lymphoma (PCNSL). From 2000 to 2017, 79 registered patients with newly diagnosed PCNSL were identified. Seventy-two patients (91 %) received chemotherapy, MPV regimen +/- rituximab was proved to 71 % (51 pts) of these. With expected and manageable toxicity profile, R-MPV frontline therapy was considered as relatively effective. Mainly because of age and poor condition, this regimen was not provided to a significant portion of patients. As per this single-center database, MPV-based chemotherapy was provided to only about 2/3 of all of the newly diagnosed PCNSL patients who were fit for the therapy and completion of at least 5 cycles was noted in only 2/3 of them that means nearly 50 % of all of the new cases. Long term survival data in this subgroup of relatively fit patients consolidated without HD-chemotherapy and ASCT are worse when compared to results from prospective clinical trials. For selected patients in complete remission, consolidation therapy conceded 2 cycles of cytarabine instead whole brain radiation therapy up to 45 Gy was provided in complete remission to avoid delayed neurotoxicity. They frequently noted late relapses after cytarabine consolidation despite some long term remissions, and so they did not recommend this approach.